Citigroup Lowers Phibro Animal Health (NASDAQ:PAHC) Price Target to $44.00

Phibro Animal Health (NASDAQ:PAHC) had its price target decreased by equities research analysts at Citigroup from $62.00 to $44.00 in a research report issued on Thursday,Benzinga reports. The brokerage currently has a “neutral” rating on the stock. Citigroup’s price target would indicate a potential upside of 28.02% from the stock’s previous close.

A number of other brokerages have also commented on PAHC. Wall Street Zen lowered Phibro Animal Health from a “strong-buy” rating to a “buy” rating in a report on Saturday, May 9th. Zacks Research raised Phibro Animal Health from a “hold” rating to a “strong-buy” rating in a report on Wednesday, March 11th. Weiss Ratings lowered Phibro Animal Health from a “buy (b)” rating to a “buy (b-)” rating in a report on Friday, May 8th. Finally, Morgan Stanley set a $49.00 target price on Phibro Animal Health in a report on Friday, February 6th. One investment analyst has rated the stock with a Strong Buy rating, two have given a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, Phibro Animal Health has a consensus rating of “Hold” and an average price target of $38.80.

Phibro Animal Health Trading Down 4.9%

NASDAQ PAHC opened at $34.37 on Thursday. Phibro Animal Health has a 52 week low of $22.51 and a 52 week high of $60.08. The stock has a market capitalization of $1.39 billion, a price-to-earnings ratio of 14.75, a PEG ratio of 0.55 and a beta of 0.61. The company has a debt-to-equity ratio of 1.97, a quick ratio of 1.26 and a current ratio of 3.17. The stock’s 50 day moving average price is $51.85 and its two-hundred day moving average price is $46.27.

Phibro Animal Health (NASDAQ:PAHC) last announced its quarterly earnings data on Wednesday, May 6th. The company reported $0.76 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.72 by $0.04. Phibro Animal Health had a return on equity of 37.14% and a net margin of 6.35%.The company had revenue of $383.54 million for the quarter, compared to analysts’ expectations of $367.02 million. Phibro Animal Health has set its FY 2026 guidance at 2.980-3.100 EPS. As a group, analysts anticipate that Phibro Animal Health will post 3.06 earnings per share for the current fiscal year.

Insider Activity at Phibro Animal Health

In other news, CEO Jack Bendheim sold 4,528 shares of Phibro Animal Health stock in a transaction dated Thursday, May 7th. The stock was sold at an average price of $48.49, for a total transaction of $219,562.72. Following the sale, the chief executive officer directly owned 56,152 shares of the company’s stock, valued at approximately $2,722,810.48. This trade represents a 7.46% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 103,088 shares of company stock worth $5,481,030 over the last quarter. Company insiders own 50.13% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors have recently modified their holdings of PAHC. Millennium Management LLC lifted its position in shares of Phibro Animal Health by 4,227.1% during the 4th quarter. Millennium Management LLC now owns 641,313 shares of the company’s stock valued at $23,959,000 after acquiring an additional 626,492 shares during the period. JPMorgan Chase & Co. lifted its position in shares of Phibro Animal Health by 1,730.9% during the 3rd quarter. JPMorgan Chase & Co. now owns 238,115 shares of the company’s stock valued at $9,634,000 after acquiring an additional 225,110 shares during the period. Allspring Global Investments Holdings LLC increased its holdings in shares of Phibro Animal Health by 145.5% during the first quarter. Allspring Global Investments Holdings LLC now owns 286,172 shares of the company’s stock valued at $15,671,000 after acquiring an additional 169,628 shares in the last quarter. Advisors Preferred LLC bought a new stake in shares of Phibro Animal Health during the third quarter valued at approximately $3,953,000. Finally, Lazard Asset Management LLC increased its holdings in shares of Phibro Animal Health by 3,392.3% during the second quarter. Lazard Asset Management LLC now owns 92,441 shares of the company’s stock valued at $2,360,000 after acquiring an additional 89,794 shares in the last quarter. Institutional investors and hedge funds own 99.34% of the company’s stock.

Phibro Animal Health Company Profile

Phibro Animal Health Corporation (NASDAQ: PAHC) is a diversified global animal health and mineral nutrition company headquartered in Teaneck, New Jersey. The company develops, manufactures and markets a broad range of pharmaceutical, mineral nutrition and performance products designed to support the health and productivity of livestock, companion animals and aquaculture species. Phibro’s portfolio includes vaccines, anti-infective therapies, coccidiostats, disinfectants, premix minerals and specialty feed additives aimed at enhancing growth, immunity and overall animal well-being.

The company operates through three principal business segments: Animal Health, Mineral Nutrition and Performance Products.